US 12,144,860 B2
ALK1 receptor and ligand antagonists and uses thereof
Asya Grinberg, Lexington, MA (US); John Knopf, Carlisle, MA (US); Robert S. Pearsall, North Reading, MA (US); Ravindra Kumar, Acton, MA (US); and Jasbir Seehra, Lexington, MA (US)
Assigned to ACCELERON PHARMA INC., Rahway, NJ (US)
Filed by Acceleron Pharma Inc., Cambridge, MA (US)
Filed on Dec. 9, 2021, as Appl. No. 17/546,983.
Application 17/546,983 is a continuation of application No. 15/686,588, filed on Aug. 25, 2017, abandoned.
Application 15/686,588 is a continuation of application No. 13/907,798, filed on May 31, 2013, abandoned.
Application 13/907,798 is a continuation of application No. 11/982,738, filed on Nov. 2, 2007, granted, now 8,455,428.
Claims priority of provisional application 60/856,592, filed on Nov. 2, 2006.
Prior Publication US 2022/0296708 A1, Sep. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 14/71 (2006.01); C07K 16/18 (2006.01)
CPC A61K 39/39558 (2013.01) [A61K 45/06 (2013.01); C07K 14/71 (2013.01); C07K 16/18 (2013.01); C07K 2317/52 (2013.01); C07K 2319/30 (2013.01)] 6 Claims
 
1. An activin-like kinase I (ALK1) fusion protein comprising the amino acid sequence of SEQ ID NO: 3.